Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Hydrocephalus during natalizumab treatment.

Zecca C, Städler C, Gobbi C.

Neurol Sci. 2010 Oct;31(5):635-7. doi: 10.1007/s10072-010-0282-9. Epub 2010 May 8.

PMID:
20454819
2.

A giant MS plaque mimicking PML during natalizumab treatment.

Twyman C, Berger JR.

J Neurol Sci. 2010 Apr 15;291(1-2):110-3. doi: 10.1016/j.jns.2010.01.001. Epub 2010 Feb 7.

PMID:
20144466
3.

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists.

Heesen C, Kleiter I, Nguyen F, Schäffler N, Kasper J, Köpke S, Gaissmaier W.

Mult Scler. 2010 Dec;16(12):1507-12. doi: 10.1177/1352458510379819. Epub 2010 Sep 8.

PMID:
20826527
4.

The pharmacovigilance program on natalizumab in Italy: 2 years of experience.

Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, Vanacore N, Covezzoli A, De Rosa M, Comi G, Pozzilli C, Bertolotto A, Marrosu MG, Grimaldi LM, Piccinni C, Montanaro N, Periotto L, Iommelli R, Addis A, Martini N, Provinciali L, Mancardi GL.

Neurol Sci. 2009 Oct;30 Suppl 2:S163-5. doi: 10.1007/s10072-009-0143-6.

PMID:
19882367
5.

Natalizumab: a country-based surveillance program.

Mancardi GL, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Provinciali L, Rossi P, Savettieri G, Tedeschi G, Tola MR, Vanacore N, Covezzoli A, De Rosa M, Piccinni C, Montanaro N, Periotto L, Addis A, Martini N.

Neurol Sci. 2008 Sep;29 Suppl 2:S235-7. doi: 10.1007/s10072-008-0948-8.

PMID:
18690503
6.

Review of progressive multifocal leukoencephalopathy and natalizumab.

Aksamit AJ.

Neurologist. 2006 Nov;12(6):293-8. Review.

PMID:
17122725
7.

JCV detection in multiple sclerosis patients treated with natalizumab.

Sadiq SA, Puccio LM, Brydon EW.

J Neurol. 2010 Jun;257(6):954-8. doi: 10.1007/s00415-009-5444-4. Epub 2010 Jan 7.

PMID:
20052484
8.

Natalizumab drug holiday in multiple sclerosis: poorly tolerated.

Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, Polman CH.

Ann Neurol. 2010 Sep;68(3):392-5. doi: 10.1002/ana.22074.

PMID:
20661928
9.

Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.

Johnson KP.

Neurologist. 2007 Jul;13(4):182-7. Review.

PMID:
17622909
10.

Natalizumab use in pediatric multiple sclerosis.

Huppke P, Stark W, Zürcher C, Huppke B, Brück W, Gärtner J.

Arch Neurol. 2008 Dec;65(12):1655-8. doi: 10.1001/archneur.65.12.1655.

PMID:
19064754
11.

Allergic and nonallergic delayed infusion reactions during natalizumab therapy.

Hellwig K, Schimrigk S, Fischer M, Haghikia A, Müller T, Chan A, Gold R.

Arch Neurol. 2008 May;65(5):656-8. doi: 10.1001/archneur.65.5.656.

PMID:
18474743
12.

Treating multiple sclerosis with natalizumab.

Iaffaldano P, Lucchese G, Trojano M.

Expert Rev Neurother. 2011 Dec;11(12):1683-92. doi: 10.1586/ern.11.154. Review.

PMID:
22091593
13.

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.

Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R.

N Engl J Med. 2009 Sep 10;361(11):1075-80. doi: 10.1056/NEJMoa0810257.

14.

Natalizumab treatment in pediatric multiple sclerosis: a case report.

Borriello G, Prosperini L, Luchetti A, Pozzilli C.

Eur J Paediatr Neurol. 2009 Jan;13(1):67-71. doi: 10.1016/j.ejpn.2008.01.007. Epub 2008 Apr 11.

PMID:
18406645
15.

Multiple sclerosis, natalizumab, and PML: helping patients decide.

Rudick RA.

Cleve Clin J Med. 2011 Nov;78 Suppl 2:S18-23. doi: 10.3949/ccjm.78.s2.05.

16.

Natalizumab dosage suspension: are we helping or hurting?

West TW, Cree BA.

Ann Neurol. 2010 Sep;68(3):395-9. doi: 10.1002/ana.22163.

PMID:
20818793
17.

Natalizumab: new drug. Multiple sclerosis: risky market approval.

[No authors listed]

Prescrire Int. 2008 Feb;17(93):7-10.

PMID:
18354844
18.

Washout period for immune-modifying drugs before natalizumab therapy.

Ilanjian H, Shane R.

Am J Health Syst Pharm. 2008 Jan 1;65(1):18-9. No abstract available.

PMID:
18159033
19.

Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis.

O'Connor P.

Expert Opin Biol Ther. 2007 Jan;7(1):123-36. Review.

PMID:
17150024

Supplemental Content

Support Center